STAG2 and Ewing sarcoma: These data are in agreement with a recent study reporting that the frequency of STAG2 protein loss in Ewing sarcoma samples analyzed by immunohistochemistry is significantly higher than the 15–20% mutation rate identified by genomic sequencing and correlates with adverse prognosis (Shulman et al, 2022).